{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:07Z","timestamp":1793383147732,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009048","name":"Mrs. Hsiu-Chin Lee Kidney Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-64640-3","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:20:40Z","timestamp":1761916840000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Finerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulation"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2537-9146","authenticated-orcid":false,"given":"Chung-An","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsuan-Wen","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1376-7780","authenticated-orcid":false,"given":"Jui-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2995-4952","authenticated-orcid":false,"given":"Li-Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ling","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Yi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-0991","authenticated-orcid":false,"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"64640_CR1","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski, J., Floege, J., Fliser, D., B\u00f6hm, M. & Marx, N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation 143, 1157\u20131172 (2021).","journal-title":"Circulation"},{"key":"64640_CR2","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie, X. et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am. J. Kidney Dis. 67, 728\u2013741 (2016).","journal-title":"Am. J. Kidney Dis."},{"key":"64640_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42989-z","volume":"13","author":"TA Mavrakanas","year":"2023","unstructured":"Mavrakanas, T. A., Tsoukas, M. A., Brophy, J. M., Sharma, A. & Gariani, K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci. Rep. 13, 15922 (2023).","journal-title":"Sci. Rep."},{"key":"64640_CR4","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris, G. L. et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N. Engl. J. Med. 383, 2219\u20132229 (2020).","journal-title":"N. Engl. J. Med."},{"key":"64640_CR5","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt, B. et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N. Engl. J. Med. 385, 2252\u20132263 (2021).","journal-title":"N. Engl. J. Med."},{"key":"64640_CR6","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1210\/clinem\/dgad144","volume":"108","author":"A Oiwa","year":"2023","unstructured":"Oiwa, A. et al. Efficacy and safety of low-dose spironolactone for chronic kidney disease in type 2 diabetes.  J. Clin. Endocrinol. Metab. 108, 2203\u20132210 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"64640_CR7","first-page":"75","volume":"22","author":"R Abolghasmi","year":"2011","unstructured":"Abolghasmi, R. & Taziki, O. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension. Saudi J. Kidney Dis. Transplant. 22, 75\u201378 (2011).","journal-title":"Saudi J. Kidney Dis. Transplant."},{"key":"64640_CR8","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi, S., Bigazzi, R. & Campese, V. M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 70, 2116\u20132123 (2006).","journal-title":"Kidney Int."},{"key":"64640_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","volume":"73","author":"NC Edwards","year":"2012","unstructured":"Edwards, N. C. et al. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br. J. Clin. Pharm. 73, 447\u2013454 (2012).","journal-title":"Br. J. Clin. Pharm."},{"key":"64640_CR10","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","volume":"30","author":"FDR Hobbs","year":"2024","unstructured":"Hobbs, F. D. R. et al. Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial. Nat. Med. 30, 3634\u20133645 (2024).","journal-title":"Nat. Med."},{"key":"64640_CR11","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx, N. et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 44, 4043\u20134140 (2023).","journal-title":"Eur. Heart J."},{"key":"64640_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1053\/j.ajkd.2023.09.003","volume":"83","author":"AK Mottl","year":"2024","unstructured":"Mottl, A. K. & Nicholas, S. B. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD. Am. J. Kidney Dis. 83, 277\u2013287 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"64640_CR13","doi-asserted-by":"crossref","unstructured":"KDIGO 2024. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117-s314 (2024).","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"64640_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur. Heart J. 43, 474\u2013484 (2022).","journal-title":"Eur. Heart J."},{"key":"64640_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ckj\/sfac234","volume":"16","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin. Kidney J. 16, 293\u2013302 (2022).","journal-title":"Clin. Kidney J."},{"key":"64640_CR16","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","volume":"96","author":"J Barrera-Chimal","year":"2019","unstructured":"Barrera-Chimal, J., Girerd, S. & Jaisser, F. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney Int. 96, 302\u2013319 (2019).","journal-title":"Kidney Int."},{"key":"64640_CR17","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","volume":"37","author":"ME Alexandrou","year":"2019","unstructured":"Alexandrou, M. E. et al. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J. Hypertens. 37, 2307\u20132324 (2019).","journal-title":"J. Hypertens."},{"key":"64640_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal, R. et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 42, 152\u2013161 (2021).","journal-title":"Eur. Heart J."},{"key":"64640_CR19","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","volume":"54","author":"NC Edwards","year":"2009","unstructured":"Edwards, N. C., Steeds, R. P., Stewart, P. M., Ferro, C. J. & Townend, J. N. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J. Am. Coll. Cardiol. 54, 505\u2013512 (2009).","journal-title":"J. Am. Coll. Cardiol."},{"key":"64640_CR20","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.amjcard.2010.07.018","volume":"106","author":"NC Edwards","year":"2010","unstructured":"Edwards, N. C. et al. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am. J. Cardiol. 106, 1505\u20131511 (2010).","journal-title":"Am. J. Cardiol."},{"key":"64640_CR21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/HJH.0000000000003643","volume":"42","author":"B Huang","year":"2024","unstructured":"Huang, B., McDowell, G., Rao, A. & Lip, G. Y. H. Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?. J. Hypertens. 42, 396\u2013398 (2024).","journal-title":"J. Hypertens."},{"key":"64640_CR22","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/ejhf.1793","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol, P. et al. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur. J. Heart Fail 22, 1378\u20131389 (2020).","journal-title":"Eur. J. Heart Fail"},{"key":"64640_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune, J. et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension 71, 599\u2013608 (2018).","journal-title":"Hypertension"},{"key":"64640_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101386","volume":"47","author":"D Parfianowicz","year":"2022","unstructured":"Parfianowicz, D. et al. Finerenone: a new era for mineralocorticoid receptor antagonism and cardiorenal protection. Curr. Probl. Cardiol. 47, 101386 (2022).","journal-title":"Curr. Probl. Cardiol."},{"key":"64640_CR25","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit, L. et al. Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J. Biol. Chem. 290, 21876\u201321889 (2015).","journal-title":"J. Biol. Chem."},{"key":"64640_CR26","doi-asserted-by":"crossref","unstructured":"Zuo, C. & Xu, G. Efficacy and safety of mineralocorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: a meta-analysis. Int. J. Clin. Pract. 29, e13413 (2019).","DOI":"10.1111\/ijcp.13413"},{"key":"64640_CR27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.2215\/CJN.00360119","volume":"14","author":"JM Norton","year":"2019","unstructured":"Norton, J. M. et al. Development and validation of a pragmatic electronic phenotype for CKD. Clin. J. Am. Soc. Nephrol. 14, 1306\u20131314 (2019).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"64640_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/13696998.2025.2451526","volume":"28","author":"D Cherney","year":"2025","unstructured":"Cherney, D. et al. Cost-effectiveness of finerenone therapy for patients with chronic kidney disease and type 2 diabetes in England & Wales: results of the FINE-CKD model. J. Med. Econ. 28, 196\u2013206 (2025).","journal-title":"J. Med. Econ."},{"key":"64640_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12933-023-02053-6","volume":"22","author":"SW Quist","year":"2023","unstructured":"Quist, S. W. et al. Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands. Cardiovasc. Diabetol. 22, 328 (2023).","journal-title":"Cardiovasc. Diabetol."},{"key":"64640_CR30","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1007\/s12325-024-02906-w","volume":"41","author":"J Ming","year":"2024","unstructured":"Ming, J. et al. Cost-effectiveness of finerenone in addition to standard of care for patients with chronic kidney disease and type 2 diabetes in China. Adv. Ther. 41, 3138\u20133158 (2024).","journal-title":"Adv. Ther."},{"key":"64640_CR31","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/dom.15997","volume":"27","author":"C Zheng","year":"2025","unstructured":"Zheng, C. et al. Cost-effectiveness of finerenone added to standard of care for patients with type 2 diabetes-related chronic kidney disease in the United States. Diabetes Obes. Metab. 27, 165\u2013173 (2025).","journal-title":"Diabetes Obes. Metab."},{"key":"64640_CR32","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s12325-024-03084-5","volume":"42","author":"A Igarashi","year":"2025","unstructured":"Igarashi, A. et al. Cost-effectiveness analysis of finerenone for treatment of chronic kidney disease in patients with type 2 diabetes from Japanese payer perspective. Adv. Ther. 42, 995\u20131008 (2025).","journal-title":"Adv. Ther."},{"key":"64640_CR33","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"Association, W.M.","year":"2013","unstructured":"Association, W.M. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310, 2191\u20132194 (2013).","journal-title":"JAMA"},{"key":"64640_CR34","doi-asserted-by":"publisher","first-page":"e2350050","DOI":"10.1001\/jamanetworkopen.2023.50050","volume":"7","author":"H-C Pan","year":"2024","unstructured":"Pan, H.-C. et al. Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease. JAMA Netw. Open 7, e2350050\u2013e2350050 (2024).","journal-title":"JAMA Netw. Open"},{"key":"64640_CR35","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jmii.2023.09.005","volume":"56","author":"VC Wu","year":"2023","unstructured":"Wu, V. C., Chen, J. Y., Lin, Y. H., Wang, C. Y. & Lai, C. C. Assessing the cardiovascular events and clinical outcomes of COVID-19 on patients with primary aldosteronism. J. Microbiol. Immunol. Infect. 56, 1158\u20131168 (2023).","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"64640_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50199-y","volume":"15","author":"HC Pan","year":"2024","unstructured":"Pan, H. C. et al. GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat. Commun. 15, 5912 (2024).","journal-title":"Nat. Commun."},{"key":"64640_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12933-024-02364-2","volume":"23","author":"HW Lai","year":"2024","unstructured":"Lai, H. W., See, C. Y., Chen, J. Y. & Wu, V. C. Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists. Cardiovasc. Diabetol. 23, 277 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"64640_CR38","doi-asserted-by":"publisher","first-page":"e2427258","DOI":"10.1001\/jamanetworkopen.2024.27258","volume":"7","author":"MH Chuang","year":"2024","unstructured":"Chuang, M. H., Chen, J. Y., Wang, H. Y., Jiang, Z. H. & Wu, V. C. Clinical outcomes of tirzepatide or glp-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw. Open 7, e2427258 (2024).","journal-title":"JAMA Netw. Open"},{"key":"64640_CR39","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12933-024-02424-7","volume":"23","author":"CA Wang","year":"2024","unstructured":"Wang, C. A., Lin, L. C., Chen, J. Y., Wang, W. J. & Wu, V. C. Exploring the mortality and cardiovascular outcomes with SGLT-2 inhibitors in patients with T2DM at dialysis commencement: a health global federated network analysis. Cardiovasc. Diabetol. 23, 327 (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"64640_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54171-8","volume":"15","author":"JY Sheu","year":"2024","unstructured":"Sheu, J. Y. et al. The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients. Nat. Commun. 15, 10043 (2024).","journal-title":"Nat. Commun."},{"key":"64640_CR41","doi-asserted-by":"crossref","unstructured":"Chang, L. Y., Liao, H. W., Chen, J. Y. & Wu, V. C. Enhanced outcomes in type 2 diabetes patients with acute kidney disease through thiazolidinedione. J. Clin. Endocrinol. Metab. 110, 2205-2214 (2024).","DOI":"10.1210\/clinem\/dgae796"},{"key":"64640_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12933-025-02649-0","volume":"24","author":"LC Lin","year":"2025","unstructured":"Lin, L. C., Chen, J. Y., Huang, T. T. & Wu, V. C. Association of glucagon-like peptide-1 receptor agonists with cardiovascular and kidney outcomes in type 2 diabetic kidney transplant recipients. Cardiovasc. Diabetol. 24, 87 (2025).","journal-title":"Cardiovasc. Diabetol."},{"key":"64640_CR43","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hern\u00e1n","year":"2022","unstructured":"Hern\u00e1n, M. A., Wang, W. & Leaf, D. E. Target trial emulation: a framework for causal inference from observational data. JAMA 328, 2446\u20132447 (2022).","journal-title":"JAMA"},{"key":"64640_CR44","doi-asserted-by":"publisher","first-page":"e2234425","DOI":"10.1001\/jamanetworkopen.2022.34425","volume":"5","author":"KL Hoffman","year":"2022","unstructured":"Hoffman, K. L. et al. Comparison of a target trial emulation framework vs Cox regression to estimate the association of corticosteroids with COVID-19 mortality. JAMA Netw. Open 5, e2234425\u2013e2234425 (2022).","journal-title":"JAMA Netw. Open"},{"key":"64640_CR45","doi-asserted-by":"publisher","first-page":"102568","DOI":"10.1016\/j.eclinm.2024.102568","volume":"71","author":"A Yang","year":"2024","unstructured":"Yang, A. et al. Clinical outcomes following discontinuation of metformin in patients with type 2 diabetes and advanced chronic kidney disease in Hong Kong: a territory-wide, retrospective cohort and target trial emulation study. EClinicalMedicine 71, 102568 (2024).","journal-title":"EClinicalMedicine"},{"key":"64640_CR46","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamainternmed.2024.6212","volume":"185","author":"Y Wang","year":"2025","unstructured":"Wang, Y. et al. Target serum urate achievement and chronic kidney disease progression in patients with gout and kidney disease. JAMA Intern. Med. 185, 74\u201382 (2025).","journal-title":"JAMA Intern. Med."},{"key":"64640_CR47","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.ajkd.2023.07.024","volume":"83","author":"JI Shin","year":"2024","unstructured":"Shin, J. I. & Grams, M. E. Trial emulation methods. Am. J. Kidney Dis. 83, 264\u2013267 (2024).","journal-title":"Am. J. Kidney Dis."},{"key":"64640_CR48","doi-asserted-by":"crossref","unstructured":"Andrade, C. Mean difference, standardized mean difference (SMD), and their use in meta-analysis: as simple as it gets. J. Clin. Psychiatry 81, 20f13681 (2020).","DOI":"10.4088\/JCP.20f13681"},{"key":"64640_CR49","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the E-value. Ann. Intern Med. 167, 268\u2013274 (2017).","journal-title":"Ann. Intern Med."},{"key":"64640_CR50","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/bcp.13152","volume":"83","author":"IS Mackenzie","year":"2017","unstructured":"Mackenzie, I. S., Morant, S. V., Wei, L., Thompson, A. M. & MacDonald, T. M. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br. J. Clin. Pharm. 83, 653\u2013663 (2017).","journal-title":"Br. J. Clin. Pharm."},{"key":"64640_CR51","doi-asserted-by":"publisher","first-page":"1237583","DOI":"10.3389\/fphar.2023.1237583","volume":"14","author":"Y Du","year":"2023","unstructured":"Du, Y., Cao, G., Gu, L., Chen, Y. & Liu, J. Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials. Front. Pharm. 14, 1237583 (2023).","journal-title":"Front. Pharm."},{"key":"64640_CR52","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamadermatol.2021.5866","volume":"158","author":"K Bommareddy","year":"2022","unstructured":"Bommareddy, K. et al. Association of spironolactone use with risk of cancer: a systematic review and meta-analysis. JAMA Dermatol. 158, 275\u2013282 (2022).","journal-title":"JAMA Dermatol."},{"key":"64640_CR53","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch, M., Tchetgen Tchetgen, E. & Cohen, T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 21, 383\u2013388 (2010).","journal-title":"Epidemiology"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64640-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64640-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64640-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:03:08Z","timestamp":1761922988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64640-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64640"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64640-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9641"}}